Why did CYAD.BR stock fall so sharply intraday?

CYAD.BR stock fell due to heavy selling in a thin market, spike in volume to **442,641**, and profit taking after recent gains. Binary biotech risk and lack of immediate positive news amplified the decline.

What are realistic price targets for CYAD.BR stock?

We outline a conservative target **€0.20**, a base case **€0.35**, and an optimistic target **€0.60** if clinical data and financing improve. Targets reflect trial risk and micro‑cap liquidity.

How does Meyka AI evaluate CYAD.BR stock?

Meyka AI rates CYAD.BR **73.57 (B+)** with a BUY suggestion. The score blends benchmark, sector, growth, key metrics, forecasts, and consensus. This is informational and not investment advice.

When is the next key date for CYAD.BR stock investors?

Celyad's next earnings announcement is scheduled for **2026-03-19**. Trial updates and press releases before that date can be major catalysts for CYAD.BR stock.

EU Stocks

Down 28.48% intraday: CYAD.BR stock €0.35 on heavy volume, watch pipeline

ByHuzaifa Zahoor February 18, 2026February 18, 2026

CYAD.BR stock plunged 28.48% intraday to €0.35 on EURONEXT as trading spiked to 442,641 shares. The move follows thin market depth and valuation re-rating despite recent pipeline progress. Celyad Oncology SA remains a clinical-stage biotech in Europe with lead CAR-T candidates in early trials. We unpack price drivers, liquidity, and what the next data and cash milestones could mean for traders and longer-term investors.